PR85110

WETTEREN, Belgium, Aug. 13, 2020 /PRNewswire=KYODO JBN/ --

Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of

biopharmaceutical contract development and manufacturing services, is pleased

to announce a major expansion of small molecule manufacturing capabilities with

the addition of a new production facility in Visakhapatnam, India. Construction

of the 8,500 square meter facility began at the end of July 2020 and is

expected to be completed mid-2022.

Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg 

To meet the current and future needs of customers, the new small molecule

manufacturing facility doubles the production capacity at the site to 310 m(3)

for active pharmaceutical ingredients (API) and intermediates and has dedicated

equipment to manage OEB 4 high potency ingredients. Further, the site has

completed renovations on existing laboratory space to support additional R&D

activities. It is estimated that the expansion will create at least 60 new jobs at the site.

The US FDA approved Ajinomoto Bio-Pharma Services India manufacturing site,

which was designed, constructed and is managed based on the Aji Bio-Pharma

Belgian sites' GMP operating standards and quality systems, has successfully

supported a number of the world's leading biopharmaceutical companies since its

formation in 2011 and continues to win awards for sustainability and quality standards.

"We are very excited to be investing in this additional production capacity to

continue delivering high quality, cost-effective small molecule manufacturing

services for our customers," said K.V.V. Raju, Head of Site Operations and CEO,

Ajinomoto Bio-Pharma India Pvt. Ltd. "This expansion exemplifies our commitment

to our vision statement of being a leading, trusted, innovative partner to our

clients and our people."

"The increased manufacturing capacity at Aji Bio-Pharma India offers a significant

advantage for our small molecule customers, who now have a variety of options

to meet their manufacturing needs," said Peter Stuyck, Sr. Vice President and

Head of European Operations, Ajinomoto Bio-Pharma Services. "This expansion

optimizes capacity across all locations and further enhances Aji Bio-Pharma's

commitment in being a leading global and quality-driven CDMO with comprehensive

service offerings."

About Ajinomoto Bio-Pharma Services

Ajinomoto Bio-Pharma Services is a fully integrated contract development and

manufacturing organization with sites in Belgium, United States, Japan, and

India, providing comprehensive development, cGMP manufacturing, and aseptic

fill finish services for small and large molecule APIs and intermediates.

Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and

capabilities for pre-clinical and pilot programs to commercial quantities,

including Corynex(R) protein expression technology, oligonucleotide synthesis,

antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis,

continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is

dedicated to providing a high level of quality and service to meet our client's

needs. Learn more: www.AjiBio-Pharma.com

SOURCE: Ajinomoto Bio-Pharma Services